The global hunter syndrome treatment market size was estimated at USD 1.31 billion in 2024 and is projected to reach USD 1.78 billion by 2030, growing at a CAGR of 5.3% from 2025 to 2030. The market’s growth is primarily driven by increasing awareness about the disease and the availability of advanced treatment options aimed at improving diagnosis, patient care, and overall management. Awareness campaigns such as the #FlyforMPS initiative have played an important role in spreading knowledge about Hunter syndrome, helping patients and caregivers recognize symptoms early and seek appropriate medical intervention.

Additionally, the continuous rise in research and development (RD) spending is fostering significant innovation in therapeutic approaches, especially in enzyme replacement therapy (ERT) and gene therapy. These advancements aim to provide more effective and long-term treatment solutions that target the underlying cause of the disease. Government support in the form of funding for rare disease research and the establishment of favorable regulatory frameworks further promotes drug discovery and development, driving sustained growth in the market.

Hunter syndrome, also known as Mucopolysaccharidosis type II (MPS II), is a rare genetic disorder that primarily affects males. The condition results from a deficiency or malfunction of the iduronate-2-sulfatase enzyme, which is essential for breaking down certain complex sugar molecules known as glycosaminoglycans (GAGs). In the absence of adequate enzyme activity, these GAGs accumulate within cells, tissues, and organs, leading to progressive damage. This buildup adversely affects multiple organ systems, including the heart, lungs, liver, and brain, resulting in severe physical and cognitive complications. The disease’s complex nature underscores the need for continuous advancements in early diagnosis, personalized treatment approaches, and supportive care strategies.

Key Market Trends Insights:

• North America dominated the global Hunter syndrome treatment market, accounting for the largest revenue share of 37.5% in 2024. This strong regional presence is primarily attributed to well-established healthcare infrastructure, high disease awareness, and the early adoption of advanced therapeutic solutions. The region benefits from significant investments in rare disease research, active participation of leading pharmaceutical companies, and supportive government initiatives that promote treatment accessibility and innovation.

• Within North America, the U.S. held the dominant position in the regional market in 2024. The country’s leadership is supported by robust clinical research activities, a high concentration of specialized treatment centers, and favorable reimbursement policies that enhance patient access to therapies. Additionally, ongoing clinical trials, collaborations between biotechnology firms and research institutions, and strong regulatory support have further strengthened the U.S. position in the global Hunter syndrome treatment landscape.

• By route of administration, the intravenous segment led the market, accounting for the largest revenue share of 72.3% in 2024. This dominance is due to the fact that most enzyme replacement therapies for Hunter syndrome are delivered intravenously to ensure effective enzyme distribution throughout the body. Intravenous administration allows for controlled dosage and rapid therapeutic action, making it the preferred route for managing this condition.

• By type, the enzyme replacement therapy (ERT) segment held the largest revenue share of 57.3% in 2024. ERT continues to be the standard of care for managing Hunter syndrome, as it directly addresses the enzyme deficiency responsible for disease progression. The increasing use of ERT, coupled with ongoing advancements aimed at improving efficacy and patient convenience, has contributed to the segment’s leading position. Furthermore, the development of next-generation ERTs and long-acting formulations is expected to strengthen its adoption in the coming years.

• By end use, the hospitals segment held a dominant position in the market, accounting for the largest revenue share of 63.1% in 2024. Hospitals serve as the primary centers for diagnosis, treatment administration, and long-term monitoring of Hunter syndrome patients. They are equipped with the necessary infrastructure and specialized medical expertise required for intravenous drug delivery and managing potential treatment-related complications. The growing availability of advanced therapies and the concentration of expert care providers in hospital settings continue to reinforce this segment’s leadership in the market.

Order a free sample PDF of the Hunter Syndrome Treatment Market Intelligence Study, published by Grand View Research.

Market Size Forecast:

• 2024 Market Size: USD 1.31 Billion

• 2030 Projected Market Size: USD 1.78 Billion

• CAGR (2025-2030): 5.3%

• North America: Largest market in 2024

• Asia Pacific: Fastest growing market

Key Companies Market Share Insights:

Some of the key players operating in the Hunter syndrome treatment market include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Abbott, Medtronic, and several others. These companies employ various strategic initiatives, including collaborations, partnerships, and alliances, to maintain a competitive edge in the market. In addition, new product launches play a critical role in expanding treatment options and addressing unmet medical needs. For example, REGENXBIO’s RGX-121 has received attention for its potential to offer a novel therapeutic approach for Hunter syndrome. These strategies, combined with ongoing research and development (RD) efforts, support innovation and enhance the availability and efficacy of treatment options for patients.

Abbott is a major player in developing innovative solutions, including enzyme replacement therapies (ERT), diagnostics, nutrition products, and branded generic pharmaceuticals. The company offers a comprehensive range of diagnostic tools that enable early detection and effective management of rare diseases such as Hunter syndrome. Abbott’s portfolio includes advanced laboratory instruments and specialized tests that allow healthcare providers to accurately identify the condition and implement timely treatment strategies. This capability plays a crucial role in improving patient outcomes and ensuring appropriate intervention at early stages of the disease.

Medtronic specializes in the development and delivery of enzyme replacement therapies and other therapeutic solutions for a variety of medical conditions, including cardiovascular, diabetes, and neurological disorders. The company’s expertise in advanced drug delivery systems is particularly valuable for administering therapies such as ERT, ensuring accurate dosing and optimal therapeutic effect. Medtronic remains committed to enhancing patient care by providing innovative solutions that improve the delivery, safety, and efficacy of treatments for rare diseases, including Hunter syndrome, thereby supporting better long-term patient outcomes.

Key Players

• Takeda Pharmaceutical Company Limited

• F. Hoffmann-La Roche Ltd

• Abbott

• Denali Therapeutics

• Medtronic

• Johnson Johnson Services, Inc.

• GSK Plc.

• Bayer AG

• Zimmer Biomet

• Stryker Corporation

• Homology Medicines, Inc.

• Novartis AG

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The Hunter syndrome treatment market is experiencing steady growth, driven by increased awareness and advancements in therapeutic options. North America leads the market due to robust healthcare infrastructure and significant research investments. Intravenous enzyme replacement therapy remains the standard treatment, with hospitals serving as primary care centers. Ongoing research and regulatory support are fostering innovation, enhancing treatment accessibility and patient outcomes.